Risk Stratification for Cardiac Valve Replacement. National Cardiac Surgery Database
|
|
- Eustace Sullivan
- 8 years ago
- Views:
Transcription
1 Risk Stratification for Cardiac Valve Replacement. National Cardiac Surgery Database W. R. Eric Jamieson, MD, Fred H. Edwards, MD, Marc Schwartz, BS, Joseph W. Bero, MS, Richard E. Clark, MD, and Frederick L. Grover, MD for the Database Committee of The Society of Thoracic Surgeons Division of Cardiovascular Surgery, University of British Columbia, Vancouver, Canada; Division of Cardiothoracic Surgery, University of Florida, Health Sciences Center, Jacksonville, Florida; Summit Medical Systems, Minneapolis, Minnesota; Cardiovascular and Pulmonary Research Center, Allegheny-Singer Research Institute, Pittsburgh, Pennsylvania; and University of Colorado Health Sciences Center, Denver, Colorado Background. The Society of Thoracic Surgeons National Database Committee is committed to risk stratification and assessment as integral elements in the practice of cardiac operations. The National Cardiac Surgery Database was created to analyze data from subscribing institutions across the country. We analyzed the database for valve replacement procedures with and without coronary artery bypass grafting to determine trends in risk stratification. Methods. The database contains complete records of 86,580 patients who had valve replacement procedures at the participating institutions between 1986 and 1995, inclusive. The 1995 harvest of data was conducted in late 1996 and available for evaluation in These records were used to conduct an in-depth analysis of risk factors associated with valve replacement and to provide prediction of operative death by using regression analysis. Regression models were made for six subgroups. Results. Adverse patient risk factors, including diabetes, hypertension and reoperation, but not ventricular function, increased over time. There were trends with regard to increasing age of the various population subsets. The types of prostheses used remained similar over time, with more mechanical prostheses than bioprostheses used for both aortic and mitral valve replacement. There was a trend toward increased use of bioprostheses in aortic replacements and decreased use in mitral replacements between 1991 and 1995 than between 1986 and The mortality rate was determined by patient subset for primary operation and reoperation and by urgency status. The modeling showed that the predicted and observed mortality correlated for all age groups and within patient subsets. Conclusions. Risk modeling is a valuable tool for predicting the probability of operative death in any individual patient. This large, multiinstitutional database is capable of determining modern operative risk and should provide standards for acceptable care. The study illustrates the importance of risk stratification for early death both for the patient and the surgeon. (Ann Thorac Surg 1999;67:943 51) 1999 by The Society of Thoracic Surgeons The operative mortality rates for cardiac valve replacement procedures have been reported from 1% to 15% depending upon valve position, multiple replacement, and concomitant coronary artery bypass. The quality assurance of valve replacement operations can be determined only by assessing the relationship between preoperative risk factors and operative mortality. Several reports have documented variables, either preoperative or intraoperative, that are independently related to increased risk of operative mortality [1 23]. The Veterans Administration study of preoperative risk assessment for cardiac operations proposed that the ratio of observed to expected mortality is a superior method to assess quality of care than unadjusted mortality [24]. That study found, by multivariate logistic regression analysis, that priority of reoperation, age, peripheral vascular disease, mitral Presented in part at the Thirty-third Annual Meeting of The Society of Thoracic Surgeons, San Diego, CA, Feb 3 5, Address reprint requests to Dr Jamieson, University of British Columbia, # West 10th Ave, Vancouver, Canada V5Z 4E3. valve replacement, and cardiomegaly were independent predictors of death for patients who had cardiac valve operations with or without coronary artery bypass grafting. We used the Society of Thoracic Surgeons (STS) National Cardiac Surgery Database to conduct a detailed analysis of risk factors associated with valve replacement operations to predict operative mortality. In the evaluation we paid particular attention to the influence of valve position, urgency, concomitant coronary artery bypass, and reoperation. The previous studies that used the STS database primarily documented risk stratification related to myocardial revascularization [25 29]. Material and Methods All patients registered in the database who had valve replacement operations between 1986 and 1995, incorporating the 1996 harvest, were considered for inclusion in the study. Patient records that had obviously conflicting information or insufficient information were excluded 1999 by The Society of Thoracic Surgeons /99/$20.00 Published by Elsevier Science Inc PII S (99)
2 944 JAMIESON ET AL Ann Thorac Surg RISK STRATIFICATION FOR VALVE REPLACEMENT 1999;67: from the study. The resultant population contained clinical information on 86,580 patients. The definition of each risk factor was consistent with the published guidelines in the STS National Cardiac Surgery Database manual for data managers. The data incorporated a classified coding system used to ensure that the patients, surgeons, and reporting institutions were not identified. The risk stratification modeling evaluated the influence of 51 preoperative variables on operative mortality by univariate and multivariate analysis for the overall population and for each subset. Subset models were developed for isolated aortic valve replacement, isolated mitral valve replacement, multiple valve replacement, aortic valve replacement with coronary artery bypass, mitral valve replacement with coronary artery bypass, multiple valve replacement with coronary artery bypass, and valve replacement with other thoracic procedures, including aortic aneurysm resection. The analysis addresses only the six primary models but the number of patients in all seven models is provided for the purpose of general comparison of incidences. Development of the Models The modeling process for risk stratification followed a standard equation, and the probability of operative mortality for each patient was calculated. The most direct approach to validation involves comparing the predicted mortality rate with the observed mortality rate for the test set, a standard training set and test set approach in which patients were randomly assigned into one of two groups of approximately equal size. The training set was used to test the model against observed results. Statistical Analysis Software (version 6.09 for Windows, SAS Institute, Cary, NC) was used for all analyses. Each preoperative variable contained in the STS database form was considered for inclusion in the models. A stepwise multivariate analysis was done to determine the patient characteristics independently associated with operative mortality. After determining the significant risk factors, a standard logistic regression analysis was done using the training set population to develop a risk equation of the form P 1/ 1 exp x where P is the probability of postoperative death, x B 0 X 0 B 1 X 1 B k X k, each B value is a constant associated with a specific risk factor, and the X values denote the status of the risk factor for a given patient. Validation of the Models The test set population was used to test the validity of the model. Risk factors for each patient in the test set were entered into the risk equation, and the probability of operative mortality for that patient was calculated. The most direct approach to validation involves comparing the predicted mortality with the observed mortality for the test set population across the risk spectrum. As shown in Figures 1 through 4, there was excellent agreement for each of the models. Fig 1. Observed operative mortality to predicted operative mortality by risk group for isolated aortic valve replacement, 1986 to The analysis sequence used in the validation process for each model incorporated first, stepwise logistic regression analysis to identify the independent risk factors; second, entry of these risk factors into the training set population to get the regression coefficient for each risk factor for that population; and third, the training set regression coefficients used to calculate the predicted mortality rate for the test set population. The test set population for each model encompassed the total population for that model. The predicted mortality rates were compared for deviation from the observed mortality rates across the entire risk spectrum. Detailed statistical descriptions of the modeling process and the validation techniques are beyond the scope of the present work. They will be presented in a separate publication. The independent risk factors in the final models are presented as odds ratios, including 95% confidence intervals. The odds ratio predicts the magnitude of influence on mortality if the risk factor was present compared with if it was absent. Results Patient Characteristics The patient populations grouped by subset model and the respective early mortality rates are given in Table 1. The total database encompassed 86,580 patients and the overall mortality was 7.5%. There were 26,317 patients with isolated aortic valve replacement (AVR) and 13,936 patients with isolated mitral valve replacement (MVR), with respective operative mortality rates of 4.3% and 6.4%. There were 3,840 patients with multiple valve replacement and the early or operative mortality rate was 9.6%. The addition of coronary artery bypass (CAB) to the valvular procedures at least doubled the early mortality rates. Valve repair or reconstruction was done either alone or
3 Ann Thorac Surg JAMIESON ET AL 1999;67: RISK STRATIFICATION FOR VALVE REPLACEMENT 945 Fig 2. Observed operative mortality to predicted operative mortality by risk group for aortic valve replacement plus coronary artery bypass, 1986 to Fig 4. Observed operative mortality to predicted operative mortality by risk group for mitral valve replacement plus coronary artery bypass, 1986 to in combination with valve replacement in another position. Aortic valve repair was done in 597 patients, with a mortality rate of 5.9%, whereas mitral valve repair was done in 4,167 patients, with a mortality rate of 3.0%. The combination of aortic valve replacement and any valve repair was done in 938 patients and the mortality rate was 7.4%. Mitral valve replacement plus any valve repair, done in 1,266 patients, had a mortality rate of 12.5%. Tricuspid valve repair was done as an isolated procedure in 144 patients, with a mortality rate of 13.9%. There were 1,723 patients with concomitant aortic valve replacement and aortic aneurysm, with a mortality rate of 9.7%. The percentage of patients with each of 51 patientrelated variables in the overall patient population was determined. Of the total population, 45.1% were older than 70 years, and 41.6% were between 50 and 70 years old. The ejection fraction was less than 30% in only 4.6% Fig 3. Observed operative mortality to predicted operative mortality by risk group for isolated mitral valve replacement, 1986 to of the population, and 19.8% were in New York Heart Association (NYHA) class IV. Previous valvular operation was done in 12.2%, and previous coronary artery bypass in 6.8%. Of the total population, 3.7% were classified as emergent status and 1.2% as emergent-salvage status. Myocardial infarction had occurred within 21 days in 4.4% of the population. Renal failure was present in 6.0% of the patients. The characteristics of patients in each of the six subset Table 1. Patient Population and Overall Operative Mortality Rates Operative Category Number Operative Mortality (%) AVR (isolated) 26, MVR (isolated) 13, Multiple valve replacement 3, AVR CAB 22, MVR CAB 8, Multiple valve replacement CAB 1, AVR any valve repair MVR any valve repair 1, Aortic valve repair Mitral valve repair 4, Tricuspid valve repair AVR aortic aneurysm repair 1, AVR other a MVR other a Overall 86, a Other includes left ventricular aneurysm, ventricular septal defect, atrial septal defect, congenital, cardiac trauma, cardiac transplant, permanent pacemaker, automatic implanted cardioverter defibrillator, aortic aneurysm, or carotid endarterectomy. Isolated aortic valve replacement and aortic aneurysm are not included in aortic valve replacement other. AVR aortic valve replacement; CAB coronary artery bypass; MVR mitral valve replacement.
4 946 JAMIESON ET AL Ann Thorac Surg RISK STRATIFICATION FOR VALVE REPLACEMENT 1999;67: Fig 5. Mean age by year and valve procedure. (AVR aortic valve replacement; CAB coronary artery bypass; MVR mitral valve replacement.) models were similar in incidence to those in the overall population. The mean age of the patients in the major models (AVR, MVR, AVR plus CAB and MVR plus CAB) by year from 1986 to 1995 are given in Figure 5. For each of the major models the age distribution by decade is shown in Figure 6. The AVR patients were older than MVR patients, and when combined with coronary artery bypass were considerably older. The age differential evaluation showed that, for the interval 1991 to 1995, the patients were older for isolated AVR, isolated MVR, CAB plus AVR, and CAB plus MVR than for the interval 1986 to 1990 ( p ). There was no age differential for multiple valve replacement and CAB plus multiple valve replacement for the time intervals. The types of prostheses used for isolated AVR and isolated MVR were similar for the two time periods, 1986 to 1990 and 1991 to In the latter time period, for aortic replacements, 59.2% were mechanical prostheses and 37.6% were bioprostheses. For mitral replacements, 73.1% were mechanical and 23.1% were bioprostheses. Homografts and autografts used for aortic valve replacement with and without concomitant valve procedures are incorporated in the bioprostheses group. There were 576 homograft AVR, with a mortality rate of 8.3% (n 48), and 71 autograft AVR, with a mortality rate of 5.6% (n 4). Table 2 compares the predominant models by time interval for the eight important patient characteristics. For the four major models (isolated AVR, isolated MVR, AVR plus CAB, and MVR plus CAB) there was no appreciable difference in mean age, gender distribution, ejection fraction, myocardial infarction within 21 days of operation and cardiogenic shock during both time intervals. The incidence of reoperation was not different for isolated AVR and isolated MVR, but it did increase when CAB was combined with AVR or MVR at the initial valve replacement operation. The incidence of diabetes mellitus and hypertension was higher in the later time interval for the four major models. Operative Mortality The mortality rate associated with each patient-related variable was determined for the overall population. The mortality rates were also determined for the six models, namely, AVR, CAB plus AVR, MVR, CAB plus MVR, multiple replacement, and CAB plus multiple replacement. The preoperative risk factors were initially evaluated for the six models by univariate analysis. Multiple stepwise logistic regression analysis was done for the procedure models to determine the significant preoperative risk factors. The predominant preoperative risk factors by procedures are stratified in Tables 3 through 5 by assessment of the odds ratios. The preoperative risk factors associated with highest operative mortality rates were salvage status, renal failure (dialysis dependent and non-dialysis dependent), emergent status, multiple reoperations, and NYHA class IV. The operative mortality rates for age groups, by decade, is shown in Table 6 for each subset model. The mortality rate increases significantly for patients over 70 years of age who had isolated aortic valve replacement and for patients over 60 years of age who had isolated mitral valve replacement or multiple valve replacement. The addition of coronary artery bypass increased the mortality rate significantly for all age groups and for all subset models. The operative mortality rate of each subset model by incidence and status is shown in Table 7. The observed and predicted mortality rates are shown by risk groups of the population size for each model in Figures 1 to 4. Comment The STS National Cardiac Surgery Database contains information from many institutions, both nonacademic and academic centers, on cardiac valve replacement operations in 86,580 patients during a 10-year period. The database provides a benchmark for quality assurance, because institutions can enter their patient population data and obtain direct risk-adjusted comparisons of their results with the national standard. Fig 6. Age distribution by valve procedure 1986 to (AVR aortic valve replacement; CAB coronary artery bypass; MVR mitral valve replacement.)
5 Ann Thorac Surg JAMIESON ET AL 1999;67: RISK STRATIFICATION FOR VALVE REPLACEMENT 947 Table 2. Comparison of Patient Characteristics by Time Intervals and Procedures Procedure Isolated aortic valve replacement (n) 3,441 22,876 Mean age (y) MI 21 days 0.8% 1.1% Mean EF 51.1% (n 1,921) 51.8% (n 15,654) Cardiogenic shock 1.1% 1.0% Female gender 39.6% 40.5% Reoperation 10.8% 13.2% Diabetes 8.6% 13.0% Hypertension 33.2% 43.3% Isolated mitral valve replacement (n) 2,217 11,719 Mean age (y) MI 21 days 1.3% 1.8% Mean EF 53.8% (n 1,294) 54.4% (n 8,110) Cardiogenic shock 1.8% 2.7% Female gender 64.2% 63.5% Reoperation 28.4% 29.0% Diabetes 8.8% 10.7% Hypertension 23.3% 32.9% Aortic valve replacement plus 2,594 20,119 coronary artery bypass (n) Mean age (y) MI 21 days 3.7% 6.9% Mean EF 48.5% (n 1,769) 49.9% (n 14,917) Cardiogenic shock 2.2% 1.3% Female gender 29.2% 31.6% Reoperation 9.7% 11.6% Diabetes 16.1% 23.4% Hypertension 41.5% 57.5% Mitral valve replacement plus 3,441 22,876 coronary artery bypass (n) Mean age (y) MI 21 days 12.4% 19.8% Mean EF 45.2% (n 906) 47.8% (n 5,704) Cardiogenic shock 7.6% 9.0% Female gender 48.0% 48.7% Reoperation 15.1% 16.7% Diabetes 19.4% 24.8% Hypertension 36.5% 52.8% EF ejection fraction; MI myocardial infarction. The patient population that had valve replacement operations has evolved during the past decade. The age differential evaluation identified that, in the past 5 years, patients who had AVR and MVR with or without myocardial revascularization were older than those who had the same procedures in previous years. These patient populations have an increased incidence of diabetes mellitus and hypertension. There has been an increase in reoperations for isolated AVR and for AVR and MVR combined with CAB. There has been no change in ventricular function in all subgroups over the decade. We evaluated 51 preoperative risk factors to determine risk models. Most of the population was over 50 years of age; 42% were between 50 and 70 years and 45% were more than 70 years of age. Of the total population, 12% had a previous valve operation and 7% had previous coronary artery bypass. Renal failure was present in 6% of the population. Of the total patient group, the urgency status was classified as emergent in 4% and emergentsalvage in 1.2%. Of the total population, 20% were classified as NYHA class IV, and 4.6% had an ejection fraction of less than 30%. The predominant preoperative risk factors associated with operative death were determined by variate analysis. Univariate and multivariate analysis were used to determine the most dominant independent predictors of early death. The risk models developed in this study defined the net effect of any given set of preoperative risk factors [26]. The model used statistical algorithms to calculate the probability of operative death. The presence or absence of risk factors for any given patient was statistically manipulated to provide a risk-adjusted estimate of mortality based on the total experience of all patients in the database. Logistic regression was used to
6 948 JAMIESON ET AL Ann Thorac Surg RISK STRATIFICATION FOR VALVE REPLACEMENT 1999;67: Table 3. Independent Risk Factors for Operative Mortality (Odds Ratios) for Isolated Aortic Valve Replacement and Aortic Valve Replacement plus Coronary Artery Bypass Aortic Valve Replacement Aortic Valve Replacement plus Coronary Artery Bypass Risk Factor Odds Ratio CI Risk Factor Odds Ratio CI Salvage status Salvage status DDRF DDRF ES Reoperation Mult reop NDRF NDRF ES Resuscitation Preop IABP First reoperation Female gender CS CS NYHA IV NYHA IV Inotropic agent used TVD CVA CVA MI Diabetes Female gender Obesity US COPD Diabetes LMD CHF PVD Arr Diuretics Age MI EF Arr Age EF Arr arrhythmia; CHF congestive heart failure; CI 95% confidence interval; COPD chronic obstructive pulmonary disease; CS cardiogenic shock; CVA cerebrovascular accident; CVD cerebrovascular disease; DDRF dialysis-dependent renal failure; EF ejection fraction; ES emergency status; HI hemodynamic instability; LMD left main disease; MI myocardial infarction; Mult reop multiple reoperation; NDRF non-dialysis-dependent renal failure; NYHA IV New York Heart Association class IV; PH pulmonary hypertension; Preop IABP preoperative intraaortic balloon pump; PVD peripheral vascular disease; TVD triple vessel disease; US urgent status. develop the statistical algorithms. The influence of changing patient characteristics in the patient population over time affects the conditional probability matrix to reflect current patient characteristics. The impact of preoperative risk factors in valve replacement operations has been reported in detail since 1985 [1 24]. There has been considerable variation in risk factors that have been identified as independent predictors of operative death. The differences in significance of risk factors among studies have resulted in confusion for individual surgeons and surgical groups. The predictors identified in the present study of the STS database will be Table 4. Independent Risk Factors for Operative Mortality (Odds Ratios) for Isolated Mitral Valve Replacement and Mitral Valve Replacement plus Coronary Artery Bypass Mitral Valve Replacement Mitral Valve Replacement plus Coronary Artery Bypass Risk Factor Odds Ratio CI Risk Factor Odds Ratio CI Salvage status Salvage status DDRF ES ES Renal failure NDRF CS Mult reop MI NYHA IV Diabetes US NYHA IV HI Female gender First reoperation CVD MI Reoperation Inotropic agent used LMD Diabetes US Age Age EF Abbreviations as in Table 3.
7 Ann Thorac Surg JAMIESON ET AL 1999;67: RISK STRATIFICATION FOR VALVE REPLACEMENT 949 Table 5. Independent Risk Factors for Operative Mortality (Odds Ratios) for Multiple Valve Replacement and Multiple Valve Replacement plus Coronary Artery Bypass Multiple Valve Replacement Multiple Valve Replacement plus Coronary Artery Bypass Risk Factor Odds Ratio CI Risk Factor Odds Ratio CI DDRF Salvage status Salvage status DDRF CS Preop IABP NDRF NDRF Mult reop NYHA IV Preop IABP Reop MI Diabetes US MI First reoperation PH NYHA IV Age Diabetes Age Abbreviations as in Table 3. compared with those identified by individual academic centers. The multivariate logistic regression analysis identified 30 independent preoperative risk factors among the six valvular models, isolated or in combination with CAB. The odds ratios of these risk factors ranged from one to over seven. One third of the preoperative risk factors had an odds ratio greater than 1.5. The remaining two thirds of the independent risk factors have odds ratios between 1 and 1.5. The upper level risk factors include salvage and emergent status, dialysis-dependent and non-dialysisdependent renal failure, reoperations (particularly multiple reoperations), and NYHA class IV. In the valvular models with concomitant CAB, high-risk factors also include cardiogenic shock, myocardial infarction, and diabetes mellitus. The lower level risk factors incorporate various combinations of the remaining predictive factors for each of the six models. The lower level risk factors include advanced age, female gender, urgent status, reduced ejection fraction, cerebrovascular accident, congestive heart failure, arrhythmias, and use of inotropic agents. Several investigators have determined independent risk factors for AVR in the general population and in the elderly, and also with concomitant CAB [1 11]. Most of those studies identified emergent procedures, advanced NYHA class, and renal failure as risk factors. Many Table 6. Operative Mortality Rate by Age Group and Valve Position and Population Size (1986 to 1995) Procedure Age (y) Overall AVR Mortality rate 3.1% 2.0% 3.0% 2.9% 3.2% 5.3% 8.5% 14.5% 4.3% Population 554 1,382 2,401 3,686 7,001 8,468 2, ,317 AVR CAB Mortality rate 21.4% 11.7% 6.1% 4.7% 5.1% 8.6% 12.5% 18.8% 8.0% Population ,709 6,120 10,617 3, ,713 MVR Mortality rate 2.3% 3.5% 3.4% 4.1% 6.1% 9.8% 13.4% 25.0% 6.4% Population ,791 2,815 4,062 3, ,936 MVR CAB Mortality rate 0.0% 13.2% 5.2% 8.6% 12.3% 18.4% 25.1% 42.9% 15.3% Population ,050 2,889 3, ,788 Multiple Mortality rate 5.7% 3.8% 5.1% 5.5% 9.9% 15.7% 23.7% 0.0% 9.6% Population ,840 Multiple CAB Mortality rate 0.0% 30.8% 5.4% 10.3% 16.5% 21.4% 26.6% 100% 18.8% Population ,424 AVR aortic valve replacement; CAB coronary artery bypass; Multiple multiple valve replacement; MVR mitral valve replacement.
8 950 JAMIESON ET AL Ann Thorac Surg RISK STRATIFICATION FOR VALVE REPLACEMENT 1999;67: Table 7. Operative Mortality Rate by Incidence and Status and Population Size (1986 to 1995) Procedure First/Elec First/Urge First/Emer First/Salv Reop/Elec Reop/Urge Reop/Emer Reop/Salv Overall AVR Mortality rate 3.3% 5.1% 15.9% 30.6% 5.9% 10.7% 22.6% 44.0% 4.3% Population 19,831 2, , ,317 AVR CAB Mortality rate 6.0% 8.9% 18.6% 51.7% 14.2% 14.3% 23.5% 57.1% 8.0% Population 15,963 3, , ,713 MVR Mortality rate 3.8% 7.5% 22.0% 43.6% 6.2% 13.3% 21.7% 35.1% 6.4% Population 8,364 1, , ,936 MVR CAB Mortality rate 10.4% 17.3% 31.9% 45.4% 14.2% 16.6% 25.6% 37.1% 15.3% Population 4,902 1, , ,788 Multiple Mortality rate 7.0% 11.0% 17.9% 33.3% 11.0% 22.5% 20.0% 62.5% 9.6% Population 2, ,840 Multiple CAB Mortality rate 13.9% 25.0% 22.5% 41.2% 22.5% 25.5% 60.0% 100% 18.8% Population ,424 AVR aortic valve replacement; CAB coronary artery bypass; Elec elective status; Emer emergency status; First first cardiac operation; Mult multiple valve replacement; MVR mitral valve replacement; Reop reoperation; Salv salvage status; Urge urgent status. reports found high-risk factors that, in the STS evaluation, were low-risk namely, advanced age, concomitant coronary artery disease, low ejection fraction, and peripheral vascular disease. In a study of predictors of mortality after AVR, Christakis and colleagues [19] reported endocarditis, previous operation, and coronary artery disease as predictors, whereas Scott and colleagues [1] found that those variables were not predictive. Endocarditis was not included as a potential risk factor in the present analysis. It is generally agreed that the risk is higher for patients with endocarditis compared with those who have an elective procedure for chronic valve disease. Coronary artery bypass also was not used in the regression model, because valve operations and valve operations plus CAB were evaluated independently. Previous operation and the requirement for CAB are definite independent predictors of early death in the present analysis, in accordance with the report by Christakis and colleagues [19]. The study by Scott and colleagues [1] is from an earlier era, 1967 to 1981, when coronary angiography was not done routinely for patients with chronic valve disease. During that time, higher mortality rates were not always explained by the risk profile of patients. These factors together with patient selection and the time period are important with regard to the final composition of any regression model. The most important predictors for MVR were the same as for AVR, namely, salvage and emergent status, renal failure and NYHA class IV. The predictors associated with MVR and CAB also included cardiogenic shock, myocardial infarction, and diabetes mellitus. The predictors reported in the literature include NYHA class IV, advanced age, urgent status, endocarditis, low ejection fraction, coronary artery disease, and cardiogenic shock [12 16]. The independent predictors of early death after multiple valve replacement and multiple valve replacement plus CAB were similar to those of isolated valve replacements. The predominant risk factors for multiple valve replacement were dialysis-dependent renal failure, salvage status, cardiogenic shock, multiple reoperations, and non-dialysis-dependent renal failure. For multiple valve replacement plus CAB the predominant predictors were salvage status, preoperative intraaortic balloon pump, dialysis-dependent and non-dialysis-dependent renal failure, reoperation, and NYHA class IV. The predictors identified in two reported series were previous operation, tricuspid valve procedure, tricuspid regurgitation, CAB, and mitral valve lesion [17, 18]. Perioperative variables have also been documented as independent predictors of operative mortality [8, 22]. The present risk stratification did not include perioperative variables in the predictive modeling. He and colleagues [9] identified cardiopulmonary bypass and ischemic time as predictors with AVR, which also included advanced age, concomitant mitral valve disease, and aortic insufficiency. Concomitant CAB doubled operative mortality rates in all valvular models (AVR, MVR, and multiple valve replacement). Concomitant AVR and aortic aneurysm resection doubled operative mortality rates over the rate for isolated AVR. In 1985, Scott and colleagues [1] found that aortic aneurysm resection was not a predictor of death after AVR. An important finding of the present study is that the mortality rate for mitral valve reconstruction is half that of isolated mitral valve replacement; however, a detailed evaluation of this observation is beyond the scope of this report. We also found that reoperative mortality rates are considerably higher for elective and urgent operations but not
9 Ann Thorac Surg JAMIESON ET AL 1999;67: RISK STRATIFICATION FOR VALVE REPLACEMENT 951 for emergent and emergent-salvage operations in all valvular models. The same observations regarding reoperations have been reported by Husebye and associates [21], Biglioli and associates [22], and Christenson and colleagues [23]. References 1. Scott WC, Miller DC, Haverich A, et al. Determinants of operative mortality for patients undergoing aortic valve replacement: discriminant analysis of 1479 operations. J Thorac Cardiovasc Surg 1985;89: Craver JM, Weintraub WS, Jones EL, Guyton RA, Hatcher CR Jr. Predictors of mortality, complications, and length of stay in aortic valve replacement for aortic stenosis. Circulation 1988;78(3 Pt 2)I Lytle BW, Cosgrove DM, Taylor PC, et al. Primary isolated aortic valve replacement: early and late results. J Thorac Cardiovasc Surg 1989;97: Galloway AC, Colvin SB, Grossi EA, et al. Ten-year experience with aortic valve replacement in 482 patients 70 years of age or older: operative risk and long-term results. Ann Thorac Surg 1990;49: Lund O, Pilegaard H, Nielsen TT, Knudsen MA, Magnussen K. Thirty-day mortality after valve replacement for aortic stenosis over the last 22 years: a multivariate risk stratification. Eur Heart J 1991;12: Bergus BO, Feng WC, Bert AA, Singh AK. Aortic valve replacement (AVR): influence of age on operative morbidity and mortality. Eur J Cardiothorac Surg 1992;6: Aranki SF, Rizzo RJ, Couper GS, et al. Aortic valve replacement in the elderly. Effect of gender and coronary artery disease on operative mortality. Circulation 1993;88 (5 pt 2):II Morris JJ, Schaff HV, Mullany CJ, et al. Determinants of survival and recovery of left ventricular function after aortic valve replacement. Ann Thorac Surg 1993;56: He GW, Acuff TE, Ryan WH, et al. Aortic valve replacement: determinants of operative mortality. Ann Thorac Surg 1994; 57: Chocron S, Etievent JP, Viel JF, et al. Aortic valve replacement in the elderly: a comparative assay of potential risk factor modification. J Heart Valve Dis 1995;4: Magovern JA, Pennock JL, Campbell DB, et al. Aortic valve replacement and combined aortic valve replacement and coronary artery bypass grafting: predicting high risk groups. J Am Coll Cardiol 1987;9: Christakis GT, Kormos RL, Weisel RD, et al. Morbidity and mortality in mitral valve surgery. Circulation 1985;72(Suppl II):II Scott WC, Miller DC, Haverich A, et al. Operative risk of mitral valve replacement: discriminant analysis of 1329 procedures. Circulation 1985;72(3 Pt 2):II Magovern JA, Pennock JL, Campbell DB, Pierce WS, Waldhausen JA. Risks of mitral valve replacement and mitral valve replacement with coronary artery bypass. Ann Thorac Surg 1985;39: Garcia Andrade I, Cartier R, Panisi P, Ennabli K, Grondin CM. Factors influencing early and late survival in patients with combined mitral valve replacement and myocardial revascularization and in those with isolated replacement. Ann Thorac Surg 1987;44: Szecsi J, Herijgers P, Sergeant P, Daene W, Scheys I, Flameng W. Mitral valve surgery combined with coronary bypass grafting: multivariate analysis of factors predicting early and late results. J Heart Valve Dis 1994;3: Teoh KH, Christakis GT, Weisel RD, et al. The determinants of mortality and morbidity after multiple-valve operations. Ann Thorac Surg 1987;43: Galloway AC, Grossi EA, Baumann FG, et al. Multiple valve operation for advanced valvular heart disease: results and risk factors in 513 patients. J Am Coll Cardiol 1992;19: Christakis GT, Weisel RD, David TE, Salerno TA, Ivanov J. Predictors of operative survival after valve replacement. Circulation 1988;78(3 pt 2):I Kirklin JK, Naftel DC, Blackstone EH, Kirklin JW, Brown RC. Risk factors for mortality after primary combined valvular and coronary artery surgery. Circulation 1989;79(6 pt 2): II Husebye DG, Pluth JR, Piehler JM, et al. Reoperation on prosthetic heart valves: an analysis of risk factors in 552 patients. J Thorac Cardiovasc Surg 1983;86: Biglioli P, Di Matteo S, Parolari A, Antona C, Arena V, Sala A. Reoperative cardiac valve surgery: a multivariable analysis of risk factors. Cardiovasc Surg 1994;2: Christenson JT, Velebit V, Maurice J, Simonet F, Schmuziger M. Valve reoperations identification of risk factors and comparison with first-time operations. Thorac Cardiovasc Surg 1994;42: Grover FL, Hammermeister KE, Burchfiel C. Initial report of the Veterans Administration Preoperative Risk Assessment Study for cardiac surgery. Ann Thorac Surg 1990;50: Edwards FH, Clark RE, Schwartz M. Practical considerations in the management of large multiinstitutional databases. Ann Thorac Surg 1994;58: Edwards FH, Clark RE, Schwartz M. Coronary artery bypass grafting: the Society of Thoracic Surgeons National Database experience. Ann Thorac Surg 1994;57: Edwards FH, Clark RE, Schwartz M. Impact of internal mammary conduits on operative mortality in coronary revascularization. Ann Thorac Surg 1994;57: Edwards FH, Carey JS, Grover FL, Bero J, Hartz RS. Impact of gender on coronary bypass operative mortality. Ann Thorac Surg 1998;66: Clarke RE. The STS Cardiac Surgery National Database: an update. Ann Thorac Surg 1995;59: Appendix. Members of the 1997 National Database Committee 1997 National Database Committee Members Frederick L. Grover (Chair), Anthony J. Acinapura, W. R. Eric Jamieson, John E. Mayer, Jr, Walter E. Pae, Jr, Joseph S. Carey, Stanley W. Dziuban, Jr, Richard H. Felns, Anthony L. Moulton, William C. Nugent, U. Scott Page, Kit V. Arom, Mercedes K. C. Dullum, Fred H. Edwards, T. Bruce Ferguson, Jr, David A. Fullerton, David H. Harpole, Jr, Constantine Mavroudis, Valerie W. Rusch, Richard P. Anderson (Ex-Officio). International Associate Members Bruce E. Keogh, Michael Polonius, Paul T. Sergeant, Hisayoshi Suma
Validation of European System for Cardiac Operative Risk Evaluation (EuroSCORE) in North American cardiac surgery q
European Journal of Cardio-thoracic Surgery 22 (2002) 101 105 www.elsevier.com/locate/ejcts Validation of European System for Cardiac Operative Risk Evaluation (EuroSCORE) in North American cardiac surgery
More informationMitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation. Michael Acker, MD For the CTSN Investigators AHA November 2013
Mitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation Michael Acker, MD For the CTSN Investigators AHA November 2013 Acknowledgements Supported by U01 HL088942 Cardiothoracic
More informationDurability of mitral valve repair for mitral regurgitation due to degenerative mitral valve disease
Keynote Lecture Series Durability of mitral valve repair for mitral regurgitation due to degenerative mitral valve disease Tirone E. David Division of Cardiovascular Surgery, Peter Munk Cardiac Centre,
More informationThe return of myocardial ischemia after coronary artery
Occurrence and Risk Factors for Reintervention After Coronary Artery Bypass Grafting Joseph F. Sabik III, MD; Eugene H. Blackstone, MD; A. Marc Gillinov, MD; Nicholas G. Smedira, MD; Bruce W. Lytle, MD
More informationCARDIAC CARE. Giving you every advantage
CARDIAC CARE Giving you every advantage Getting to the heart of the matter The Cardiovascular Program at Northwest Hospital & Medical Center is dedicated to the management of cardiovascular disease. The
More informationThe STS Mitral Repair/Replacement Composite Score: A Report of the STS Quality Measurement Task Force
The STS Mitral Repair/Replacement Composite Score: A Report of the STS Quality Measurement Task Force 1 Vinay Badhwar, MD, 2 J. Scott Rankin, MD, 3 Xia He, MS, 4 Jeffrey P. Jacobs, MD, 5 James S. Gammie,
More informationAnalysis of Mitral Valve Replacement Outcomes is Enhanced by Meaningful Clinical Use of Electronic Health Records
credits available for this article see page 88. Original RESEARCH & CONTRIBUTIONS Analysis of Mitral Valve Replacement Outcomes is Enhanced by Meaningful Clinical Use of Electronic Health Records John
More informationPerioperative Cardiac Evaluation
Perioperative Cardiac Evaluation Caroline McKillop Advisor: Dr. Tam Psenka 10-3-2007 Importance of Cardiac Guidelines -Used multiple times every day -Patient Safety -Part of Surgical Care Improvement Project
More informationCardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg
Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate
More informationSteven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From the CoreValve US Pivotal Trial Steven J. Yakubov,
More informationSpecific Basic Standards for Osteopathic Fellowship Training in Cardiology
Specific Basic Standards for Osteopathic Fellowship Training in Cardiology American Osteopathic Association and American College of Osteopathic Internists BOT 07/2006 Rev. BOT 03/2009 Rev. BOT 07/2011
More informationTranscatheter Mitral Valve-in-Valve and Valve-in-Ring Implantations. Danny Dvir, MD On behalf of VIVID registry investigators
Transcatheter Mitral Valve-in-Valve and Valve-in-Ring Implantations Danny Dvir, MD On behalf of VIVID registry investigators Introduction Bioprosthetic valves are increasingly implanted in open-heart surgeries.
More informationListen to your heart: Good Cardiovascular Health for Life
Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular
More informationDeterminants of duration of ICU stay after coronary artery bypass graft surgery
British Journal of Anaesthesia 1996; 77: 208 212 Determinants of duration of ICU stay after coronary artery bypass graft surgery A. MICHALOPOULOS, G. TZELEPIS, G. PAVLIDES, J. KRIARAS, U. DAFNI AND S.
More informationBASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY
BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY American Osteopathic Association and the American College of Osteopathic Internists Specific Requirements For Osteopathic Subspecialty Training In Cardiology
More informationECG may be indicated for patients with cardiovascular risk factors
eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,
More informationObjectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
More informationSurgeons Role in Atrial Fibrillation
Atrial Fibrillation Surgeons Role in Atrial Fibrillation Steven J Feldhaus, MD, FACS 2015 Cardiac Symposium September 18, 2015 Stages of Atrial Fibrillation Paroxysmal (Intermittent) Persistent (Continuous)
More informationPatients with end-stage renal disease (ESRD) are at high
Long-Term Outcome of Renal Transplant Recipients in the United States After Coronary Revascularization Procedures Charles A. Herzog, MD; Jennie Z. Ma, PhD; Allan J. Collins, MD Background Retrospective
More informationTreating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationHA Territory-wide PCI Audit 2003-05
HA Territory-wide PCI Audit 23-5 5 PCI Audit Working Group Central Committee (Cardiac Services) HA Convention 26 Percutaneous Coronary Intervention Background HA AP target 2/3, coordinated by PCI Working
More informationPHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
More informationEuropean system for cardiac operative risk evaluation (EuroSCORE) q
European Journal of Cardio-thoracic Surgery 16 (1999) 9±13 European system for cardiac operative risk evaluation (EuroSCORE) q S.A.M. Nashef*, F. Roques, P. Michel, E. Gauducheau, S. Lemeshow, R. Salamon,
More informationAtherosclerosis of the aorta. Artur Evangelista
Atherosclerosis of the aorta Artur Evangelista Atherosclerosis of the aorta Diagnosis Classification Prevalence Risk factors Marker of generalized atherosclerosis Risk of embolism Therapy Diagnosis Atherosclerosis
More informationProvider Checklist-Outpatient Imaging. Checklist: Nuclear Stress Test, Thallium/Technetium/Sestamibi (CPT Code 78451-78454 78469)
Provider Checklist-Outpatient Imaging Checklist: Nuclear Stress Test, Thallium/Technetium/Sestamibi (CPT Code 78451-78454 78469) Medical Review Note: Per InterQual, if any of the following are present,
More informationThe Cardiac Society of Australia and New Zealand
The Cardiac Society of Australia and New Zealand Guidelines on Support Facilities for Coronary Angiography and Percutaneous Coronary Intervention (PCI) including Guidelines on the Performance of Procedures
More informationContemporary Management of Cardiovascular Disease
Contemporary Management of Cardiovascular Disease NOVEMBER 20 21, 2015 Hilton Anatole Hotel Register Today! ccfcme.org/gocvdtx Contemporary Management of Cardiovascular Disease Join us on November 20-21
More informationType II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease
Heart Failure Center Hadassah University Hospital Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Israel Gotsman MD The Heart Failure Center, Heart Institute Hadassah University
More informationSpecialty Excellence Award and America s 100 Best Hospitals for Specialty Care 2013-2014 Methodology Contents
Specialty Excellence Award and America s 100 Best Hospitals for Specialty Care 2013-2014 Methodology Contents Introduction... 2 Specialty Excellence Award Determination... 3 America s 100 Best Hospitals
More informationCARDIAC RISKS OF NON CARDIAC SURGERY
CARDIAC RISKS OF NON CARDIAC SURGERY N E W S T U D I E S & N E W G U I D E L I N E S W. B. C A L H O U N, M D, F A C C 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management
More informationCardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease
Cardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease What is Cardiac Rehabilitation? Cardiac rehabilitation is a comprehensive exercise, education, and behavior modification
More informationMichigan Heart & Vascular Institute ON THE ST. JOSEPH MERCY HOSPITAL CAMPUS, ANN ARBOR, MICHIGAN
ON THE ST. JOSEPH MERCY HOSPITAL CAMPUS, ANN ARBOR, MICHIGAN Dear Colleague: Cardiovascular medicine has marked an important milestone in the battle against heart disease. The latest available data indicates
More informationThe Difficult Mitral Valve Repair in Children, Leave with Stenosis or Regurgitation
The Difficult Mitral Valve Repair in Children, Leave with Stenosis or Regurgitation Abdullah A. Alghamdi, MD, MSc, FRCSC King Abdulaziz Cardiac Center, National Guard Riyadh, Saudi Arabia Outlines Not
More informationRisk strati cation in heart surgery: comparison of six score systems q
European Journal of Cardio-thoracic Surgery 17 (2000) 400±406 Risk strati cation in heart surgery: comparison of six score systems q Hans J. Geissler*, Philipp HoÈlzl, Sascha Marohl, Ferdinand Kuhn-ReÂgnier,
More informationCardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone
James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest
More informationMEDICAL POLICY SUBJECT: CARDIAC REHABILITATION. POLICY NUMBER: 8.01.14 CATEGORY: Therapy/ Rehabilitation
MEDICAL POLICY SUBJECT: CARDIAC REHABILITATION PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy
More informationEndovascular Repair of an Axillary Artery Aneurysm: A Novel Approach
Endovascular Repair of an Axillary Artery Aneurysm: A Novel Approach Bao- Thuy D. Hoang, MD 1, Jonathan- Hien Vu, MD 2, Jerry Matteo, MD 3 1 Department of Surgery, University of Florida College of Medicine,
More information4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa 1999. Objectives. No disclosures, no conflicts
Cardiac Rehabilitation: From the other side of the glass door No disclosures, no conflicts Charles X. Kim, MD, FACC, ABVM Objectives 1. Illustrate common CV benefits of CV rehab in real world practice.
More informationUNMH Cardiothoracic Surgery Clinical Privileges
All new applicants must meet the following requirements as approved by the UNMH Board of Trustees effective: 02/20/2015 INSTRUCTIONS Applicant: Check off the "Requested" box for each privilege requested.
More informationINTRODUCTION TO EECP THERAPY
INTRODUCTION TO EECP THERAPY is an FDA cleared, Medicare approved, non-invasive medical therapy for the treatment of stable and unstable angina, congestive heart failure, acute myocardial infarction, and
More information06 Validation of risk prediction model
HA Territory-wide PCI Audit 2003-06 06 Validation of risk prediction model PCI Audit Working Group Central Committee (Cardiac Services) HA Convention 2007 Background Participants: All HA hospitals via
More informationOverview. Total Joint Replacement in the U.S. KP National Total Joint Registry EMR Tools and Outcome Assessment: A Model for Vascular Surgery?
KP National Total Joint Registry EMR Tools and Outcome Assessment: A Model for Vascular Surgery? Liz Paxton Director of Surgical Outcomes and Analysis Overview KP Total Joint Replacement Registry Background
More informationJournal of the American College of Cardiology Vol. 38, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.
Journal of the American College of Cardiology Vol. 38, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01408-5 Prognostic
More informationMinimally Invasive Mitral Valve Surgery
Minimally Invasive Mitral Valve Surgery Stanford Health Care offers leading, superior options in cardiac surgery, including the latest techniques and research for Minimally Invasive Cardiac surgery. Advanced
More informationCardiac Catheterization Curriculum for Fellows in Cardiology Dartmouth-Hitchcock Medical Center Level 1 and Level 2 Training 2008-2009
Cardiac Catheterization Curriculum for Fellows in Cardiology Dartmouth-Hitchcock Medical Center Level 1 and Level 2 Training 2008-2009 I. Overview of Training in Cardiac Catheterization Cardiac catheterization
More informationAdvances in Quality & Outcomes Conference
The Society of Thoracic Surgeons Advances in Quality & Outcomes Conference (Formerly known as the Data Managers Meeting) Revised Program September 14, 2007 November 1-3, 2007, Marriott Minneapolis City
More informationStroke and Atrial Fibrillation Following Cardiac Surgery
Stroke and Atrial Fibrillation Following Cardiac Surgery David K. Murdock, MD; L. Rosemary Rengel, BA; Audrey Schlund, RN; Karen J. Olson, RN, BSN; Jeffrey W. Kaliebe, MT; John A. Johnkoski, MD; Fernando
More informationAdult Cardiac Surgery ICD9 to ICD10 Crosswalks
164.1 Malignant neoplasm of heart C38.0 Malignant neoplasm of heart 164.1 Malignant neoplasm of heart C45.2 Mesothelioma of pericardium 198.89 Secondary malignant neoplasm of other specified sites C79.89
More informationCalifornia Health and Safety Code, Section 1256.01
California Health and Safety Code, Section 1256.01 1256.01. (a) The Elective Percutaneous Coronary Intervention (PCI) Pilot Program is hereby established in the department. The purpose of the pilot program
More informationIs Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient?
Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient? --- NIRS-IVUS TVC Imaging Adds Additional Information for the Heart Team Dr. Luis Tami Memorial Regional Hospital
More informationINNOVATIONS IN THE ENVIRONMENT: HOW THE HYBRID OPERATING ROOM CAN INFLUENCE CARDIAC SURGERY
CLAUDIO GROSSI Cardiac Surgery Ospedale Santa Croce CUNEO (Italy) INNOVATIONS IN THE ENVIRONMENT: HOW THE HYBRID OPERATING ROOM CAN INFLUENCE CARDIAC SURGERY Impossibile visualizzare l'immagine. La memoria
More informationHow should we treat atrial fibrillation in heart failure
Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 23/24 Ottobre 2015 How should we treat atrial fibrillation in heart failure Matteo Anselmino Dipartimento Scienze Mediche Città
More informationImpact of Massachusetts Health Care Reform on Racial, Ethnic and Socioeconomic Disparities in Cardiovascular Care
Impact of Massachusetts Health Care Reform on Racial, Ethnic and Socioeconomic Disparities in Cardiovascular Care Michelle A. Albert MD MPH Treacy S. Silbaugh B.S, John Z. Ayanian MD MPP, Ann Lovett RN
More informationAutomatic External Defibrillators
Last Review Date: May 27, 2016 Number: MG.MM.DM.10dC2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationManagement of Pacing Wires After Cardiac Surgery
Management of Pacing Wires After Cardiac Surgery David E. Lizotte, Jr. PA C, MPAS, FAPACVS President, Association of Physician Assistants in Cardiovascular Surgery Conflicts: None Indications 2008 Journal
More informationMADIT-II CLINICAL SUMMARY
CAUTION: Federal law restricts this device to sale by or on the order of a physician trained or experienced in device implant and follow-up procedures. CLINICAL SUMMARY MADIT-II Boston Scientific Corporation
More informationPrognostic impact of uric acid in patients with stable coronary artery disease
Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,
More informationPreoperative Pulmonary Evaluation: Truth and Fiction. What are this patientʼs risks? Goals for Today
Preoperative Pulmonary Evaluation: Truth and Fiction Nichole G. Zehnder, MD Instructor in Internal Medicine Division of Hospital Medicine University of Colorado at Denver Hospital Medicine Group What are
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationRATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
More informationPre-Operative Cardiac Evaluation Kalpana Jain, MD
Pre-Operative Cardiac Evaluation Kalpana Jain, MD Cardiac evaluation is an integral part of pre-op evaluation. Perioperative cardiac events are common causes of mortality. Major cardiac complications associated
More informationClinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013. Reference: NHSCB/A09/PS/b
Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013 Reference: NHS Commissioning Board Clinical Commissioning Policy Statement: Percutaneous
More informationSTS/AATS CODING. NEWSLETTER Recent Information on CPT and ICD-9 CM Codes for Cardiothoracic Surgeons
N E W S STS/AATS CODING L E T T E R Vol. 13 No. 1, Spring 2004 2004, The Society of Thoracic Surgeons, Chicago, IL 60611 TEE s; Maze; 0,10, XXX Global Periods; Medicare Usage for Assistants-at- Surgery
More informationCommon types of congenital heart defects
Common types of congenital heart defects Congenital heart defects are abnormalities that develop before birth. They can occur in the heart's chambers, valves or blood vessels. A baby may be born with only
More informationCURRICULUM VITAE. 1969-1973 University of Michigan Ann Arbor, Michigan B.S., Psychology with Honors, May, 1973
Brian Lloyd Tell, M.D. Twin Cities Heart & Lung Clinic 4040 Coon Rapids Boulevard NW, #120 Coon Rapids, Minnesota 55433 Ph: 763/236-9500 Fax: 763/236-9515 CURRICULUM VITAE Education: 1966-1969 Jamaica
More informationCARDIAC & THORACIC SURGERY REFERRAL AND CONSULTATION GUIDE 2011-2012
CARDIAC & THORACIC SURGERY REFERRAL AND CONSULTATION GUIDE 2011-2012 Dear Colleague, We are pleased to provide you with the Cardiac and Thoracic Surgery Referral and Consultation Guide for the University
More informationGlucose Control Lowers the Risk of Wound Infection in Diabetics After Open Heart Operations
Glucose Control Lowers the Risk of Wound Infection in Diabetics After Open Heart Operations Kathryn J. Zerr, MBA, Anthony P. Furnary, MD, Gary L. Grunkemeier, PhD, Stephen Bookin, MD, Vivek Kanhere, MD,
More informationPerioperative Risk Stratification for Noncardiac Surgical Patients with Cardiac Diagnosis. Michael A. Blazing
Perioperative Risk Stratification for Noncardiac Surgical Patients with Cardiac Diagnosis Michael A. Blazing Outline The coming crush A practical approach to clinical risk assessment Classic approach to
More informationPRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf
More informationCARDIOLOGY ROTATION GOALS AND OBJECTIVES
CARDIOLOGY ROTATION GOALS AND OBJECTIVES PGY-1 Core Medicine Rotation The trainee will have the opportunity to develop clinical skills, the ability to analyze patients problems, and make treatment plans
More informationCardiac Services. Adult Cardiac Surgery. Activity Report 2009-10
Cardiac Services Adult Cardiac Surgery Activity Report 2009-10 Photo by Paul Highnam A J Bryan, DM FRCS Consultant Cardiac Surgeon Prepared by A M Cohen, FRCA Consultant Cardiac Anaesthetist Alan Davies
More informationChristopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona
Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona Areas to be covered Historical, current, and future treatments for various cardiovascular disease: Atherosclerosis (Coronary
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationPhysician and other health professional services
O n l i n e A p p e n d i x e s 4 Physician and other health professional services 4-A O n l i n e A p p e n d i x Access to physician and other health professional services 4 a1 Access to physician care
More informationATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)
ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) By Prof. Dr. Helmy A. Bakr Mansoura Universirty 2014 AF Classification: Mechanisms of AF : Selected Risk Factors and Biomarkers for AF: WHY AF? 1. Atrial fibrillation
More information2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation.
DISCLOSURES I have no relevant financial relationships to disclose. Cardiac Evaluation of Potential Solid Organ Transplant Recipients Michele Hamilton, MD Director, Heart Failure Program Cedars Sinai Heart
More informationEndoskopische Venenentnahme der V. saphena in der koronaren Bypasschirurgie - Aktuelle Datenlage - Dr. med. Stefanie Reutter
Endoskopische Venenentnahme der V. saphena in der koronaren Bypasschirurgie - Aktuelle Datenlage - Dr. med. Stefanie Reutter Endoskopische Venenentnahme (EVH) - Einführung 1979 Tevaearai und Kollegen haben
More informationCardiac Rehabilitation: Strategies Approaching 2020
ACC Banff 2015 Cardiac Rehabilitation: Strategies Approaching 2020 James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Libin Cardiovascular
More informationDenominator Statement: Cardiac surgery patients with no evidence of prior infection.
Last Updated: Version 4.3b NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Information Form CMS/The Joint Commission: Suspended (Effective immediately beginning with July 1, 2014 discharges)
More informationHeart & Vascular Institute. 2012 Outcomes
Heart & Vascular Institute & 212 Outcomes Measuring Outcomes Promotes Quality Improvement Measuring and understanding outcomes of medical treatments promotes quality improvement. Cleveland Clinic has created
More informationPreoperative Laboratory and Diagnostic Studies
Preoperative Laboratory and Diagnostic Studies Preoperative Labratorey and Diagnostic Studies The concept of standardized testing in all presurgical patients regardless of age or medical condition is no
More informationUNIVERSITA' DEGLI STUDI DI ROMA TOR VERGATA
SYSTEMATIC PATHOLOGY I IIIYear Scientific Field DISCIPLINE TUTOR Systematic Pathology I MED/21 MED/10 Thoracic Surgery Respiratory Diseases Tommaso Claudio Mineo Paola Rogliani MED/10 Respiratory Diseases
More informationPREOPERATIVE CARDIAC RISK FOR NONCARDIAC SURGERY Review of 2014 ACC/AHA Guidelines and Implications for Clinical Care
PREOPERATIVE CARDIAC RISK FOR NONCARDIAC SURGERY Review of 2014 ACC/AHA Guidelines and Implications for Clinical Care Ronald L Walsh, D.O., MACOI, FACC ACOI Clinical Challenges in Inpatient Care March
More informationEVALUATION OF MEDICAL RECORDS COMPLETENESS IN THE ADULT CARDIOLOGY CLINIC AT NORK MARASH MEDICAL CENTER
American University of Armenia Center for Health Services Research and Development Nork Marash Medical Center EVALUATION OF MEDICAL RECORDS COMPLETENESS IN THE ADULT CARDIOLOGY CLINIC AT NORK MARASH MEDICAL
More informationCardiac Rehabilitation CARDIAC REHABILITATION HS-091. Policy Number: HS-091. Original Effective Date: 3/16/2009
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. M issouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationThe Congenital Heart Surgeons Society (CHSS) Datacenter
The Congenital Heart Surgeons Society Datacenter: Unique Attributes as a Research Organization Christopher A. Caldarone, MD, and William G. Williams, MD Over the last 25 years, the Congenital Heart Surgeons
More informationThoracoabdominal aortic aneurysm
Thoracoabdominal aortic aneurysm Patient (1) - 69 PMH: 2013 - MVP, aortic root replacement with biological valve (Perimount) and subtotal aortic arch replacement Analysis for oppressive chest complaints
More informationAortic Valve Stenosis and CAD
EUROECHO 14, Copenhagen 2010 Aortic Valve Stenosis and CAD Aleksandar N. Neskovic Clinical Hospital Center Zemun Belgrade University School of Medicine Aortic Stenosis and CAD Important facts Links AS/CAD
More informationStrategic Implementation and Automation of an Administrative Database into Practice while Minimizing Human- Resources
Strategic Implementation and Automation of an Administrative Database into Practice while Minimizing Human- Resources JONATHAN GOSS, MS4 YAZAN DUWAYRI, MD Data Abstraction How does it make you feel? The
More informationPerfusion Downunder Collaboration Database Data Quality Assurance: Towards a High Quality Clinical Database
The Journal of ExtraCorporeal Technology Perfusion Downunder Collaboration Database Data Quality Assurance: Towards a High Quality Clinical Database Sigrid C. Tuble, PhD, CCRC Department of Cardiac and
More informationCARDIA 288 MONTH FOLLOW-UP SUPPLEMENTAL FORM (FORM B) HOSPITALIZATION CASE #: INTERVIEWER ID FY288BIVID2. Page 1 of 6 FY288BH4CN
HOSPITALIZATION CASE #: 2 8 8 0 H FY288BH4CN Has the participant indicated any of the following reasons for being admitted overnight for this case? 1. Suspected or confirmed problems with the heart, circulation,
More informationACLS Defibrillation Protocols With the ZOLL Rectilinear Biphasic Waveform AHA/ERC Guidelines 2005
ACLS Defibrillation Protocols With the ZOLL Rectilinear Biphasic Waveform AHA/ERC Guidelines 2005 Introduction: The purpose of this document is to outline the equivalent biphasic protocols specific to
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationAntiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
More informationREFLECTIONS: FORTY YEARS OF VASCULAR CARE
REFLECTIONS: FORTY YEARS OF VASCULAR CARE REFLECTIONS: FORTY YEARS OF VASCULAR CARE CEA AAA CEA AAA REDDY WHITEHOUSE ZELENOCK ZITO CEA AAA EVAR CEA CAS AAA VASCULAR SURGERY AS A SPECIALTY NON-INVASIVE
More informationCOMMON METHODOLOGICAL ISSUES FOR CER IN BIG DATA
COMMON METHODOLOGICAL ISSUES FOR CER IN BIG DATA Harvard Medical School and Harvard School of Public Health sharon@hcp.med.harvard.edu December 2013 1 / 16 OUTLINE UNCERTAINTY AND SELECTIVE INFERENCE 1
More informationNon-Invasive Risk Predictors in (Children with) Pulmonary Hypertension
Ideal risk prognosticator Easy to acquire Non-Invasive Risk Predictors in (Children with) Pulmonary Hypertension Safe -- Non-invasive Robust Gerhard-Paul Diller Astrid Lammers Division of Adult Congenital
More informationZhongmin Li, PhD University of California, Davis School of Medicine Zhongmin.li@ucdmc.ucdavis.edu
Zhongmin Li, PhD University of California, Davis School of Medicine Zhongmin.li@ucdmc.ucdavis.edu 1 Health care quality and transparency of care and outcomes AHRQ s IQI and PSIs State initiatives Multiple
More information